Soft Tissue Augmentation: The International Perspective, Introduction
For the last few decades, aesthetic dermatology has become increasingly popular. Most of our patients want to enhance their look without downtime.
Biocompatibility of Microparticles into Soft Tissue Fillers
The increasing need for long-lasting injectable soft tissue fillers for the treatment of wrinkles and folds requires a critical discussion of the biocompatibility on a scientific background.
Hyaluronic Acid and Its Use as a “Rejuvenation” Agent in Cosmetic Dermatology
Since 1996, hyaluronic acid (HA) has been launched onto the market in Europe. Since then, different companies proposed their HAs. Biomatrix (NJ, USA) proposes an animal-derived HA (from rooster comb). Q–Med AB (Uppsala, Sweden) and LEA-DERM (Paris, France) are the main companies to have a nonanimal HA.
The Use of Poly-L-Lactic Acid in the Management of Soft-Tissue Augmentation: A Five-Year Experience
Poly-L-lactic acid (PLA) New-Fill* is one of the latest implants commercialized among bioresorbable fillers. This synthetic polymer is biocompatible, biodegradable, immunologically inert, and free from toxicity.
Polymethyl Methacrylate Microspheres in Collagen
Artecoll was developed about 20 years ago and underwent a number of production changes until it recently became FDA approved under the new name of Artefill.